A detailed structural and functional analysis of VHL mutations and their effects on hypoxia inducible factor-α in sporadic clear cell renal carcinoma : Number 1: Young Investigator Award
SETD2, a histone methyltransferase, is misregulated in advanced clear cell renal cell carcinoma (ccRCC) : Number 2: Young Investigator Award
Serum proteomics classifies outcome in renal cell carcinoma (RCC) patients receiving sunitinib and erlotinib : Number 3: Young Investigator Award
Impact of targeted therapy on overall survival in advanced kidney cancer; a population based analysis of the national Surveillance Epidemiology and End Results (SEER) registry database : Number 4: Young Investigator Award
Quantitative gene expression using RT-PCR refines the prediction of recurrence risk in resected T1 clear cell renal cell carcinoma (ccRCC) : Number 5
Real-world presurgical characteristics and postsurgical morbidity of 10,404 Americans undergoing nephrectomy because of renal tumors : Number 6
Type 1 cytokine response and myeloid derived suppressor cells (MDSC) in patients with metastatic renal cell carcinoma (mRCC) with pazopanib or temsirolimus treatment : Number 7
Anti-tumor activity observed in an ongoing phase 1 drug-drug interaction study of cabozantinib (XL184) and rosiglitazone in patients (pts) with renal cell carcinoma : Number 8
Subgroup analysis of the phase 3 RECORD-1 trial of everolimus in patients with metastatic renal cell carcinoma: 1 versus 2 prior vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies : Number 9
‘Real World’ treatment of metastatic renal cell carcinoma (mRCC) in community and academic settings : Number 10
A pooled analysis of the efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma (mRCC) : Number 11
Clinicopathological feature of T1a renal cell carcinoma : Number 12
The renal nephrometry scoring system is predictive of partial nephrectomy complexity : Number 13
Impact of tumour size on metastases and locally advanced growth in renal cell carcinoma up to 7 cm : Number 14
Decreased incidence of renal cell carcinoma in Sweden 1980-2000 : Number 15
A multicenter, open-label, randomized phase 3 trial comparing the safety and efficacy of dovitinib (TKI258) versus sorafenib in patients with metastatic renal cell carcinoma after failure of anti-angiogenic (VEGF-targeted and mTOR inhibitor) therapies : Number 16
Prognostic factors for progression-free survival (PFS), overall survival (OS), and long-term OS (LT-OS) with sunitinib in 1,059 patients, treated on clinical trials, with metastatic renal cell carcinoma (mRCC) : Number 17
Final analysis of the phase 2 randomized discontinuation trial of tivozanib (AV-951) versus placebo in patients with renal cell carcinoma : Number 18
Relationship between Karnofsky Performance Status (KPS) and tumor response: analysis of the RECORD-1 phase 3 trial of everolimus in patients with advanced renal cell carcinoma (RCC) : Number 19
The role of Src kinase in renal cell cancer : Number 20
NOTE: TRIALS IN PROGRESS SUBMISSION EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, a SWOG III Adjuvant Study (S0931) : Number 21
Phase 1 trial of tivozanib (AV-951) combined with temsirolimus in patients with renal cell carcinoma : Number 22
A dynamic tumor model of the RECORD-1 phase 3 trial in patients with metastatic renal cell carcinoma (mRCC): quantification of the effect of everolimus on tumor growth and new metastases : Number 23
Glycogen provides nutritional support to renal cancer cells under conditions of stress and may serve as a marker of response to anti-angiogenic therapy with bevacizumab : Number 24
Effects of fibroblast growth factor on the angiogenesis and proliferation of human renal cancer cells : Number 25
Practice-setting and surgeon characteristics heavily influence the decision to perform partial nephrectomy among AUA surgeons : Number 26
Trade-offs between toxicity and progression-free survival in renal cell carcinoma therapies: a choice-format conjoint study of patient preferences : Number 27
Comparison of hilar clamping and non-hilar clamping partial nephrectomy for tumors involving a solitary kidney : Number 28
Management of renal masses during pregnancy: the role of partial nephrectomy : Number 29
Conservative management of urinary fistulae after open partial nephrectomy for renal cortical masses : Number 30